Targeted Perfusion Based Haemodynamic Management in Critically Ill Patients Using Urethral Perfusion

Targeted Perfusion Based Haemodynamic Management in Critically Ill Patients Using Urethral Perfusion - a Pilot Study

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06158555

Acronym

TARGET UP

Enrollment

Registered

2023-12-06

Start date

2023-04-01

Completion date

2024-12-01

Last updated

2024-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critically Ill

Brief summary

To assess the safety and feasibility of the IKORUS device in critically ill patients and to gather exploratory data on haemodynamic coherence

Interventions

DRUG250 ML NaCl 4.5 MG/ML Injection

Bolus 250 ml crystalloid. Usually 0.9% saline or compound sodium lactate solution at discretion of attending clinician

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Within 24 h of ICU admission * Predicted length of ICU stay at least 5 days * Receiving \>0.1 mcg/kg/min of noradrenaline at time of study enrolment

Exclusion criteria

* Palliative treatment intent * Contra indication to urethral catheterisation or complication during previous urethral catheter insertion * Contraindication to fluid or vasopressor challenges in the opinion of the attending clinician

Design outcomes

Primary

Measure	Time frame
Change to Urethral Perfusion Index	5 minutes after fluid challenge administration

Countries

United Kingdom

Contacts

Primary ContactSam Hutchings, PhD

sam.hutchings@nhs.net020329994957

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026